Business

Moderna stock falls 20% as it slashes guidance on low EU sales, tough U.S. vaccine market

Moderna now expects 2024 product revenue to come in between $3 billion and $3.5 billion, down from a previous guidance of $4 billion. 

adminadmin
Aug 2, 2024 - 06:00
 0  9
Moderna stock falls 20% as it slashes guidance on low EU sales, tough U.S. vaccine market
Moderna now expects 2024 product revenue to come in between $3 billion and $3.5 billion, down from a previous guidance of $4 billion. 
Read More

Tags:

Previous Article

Kohl's bets on Babies R Us as it tries to attract younger families, higher sales

Next Article

UConn basketball's Paige Bueckers to sign NIL deal with Unrivaled league, receiv...

admin
admin

Related Posts

Automakers are getting back into advertising’s biggest arena: NFL

Automakers are getting back into advertising’s biggest ...

admin Sep 7, 2024  0  7

Novavax says FDA put hold on combination Covid-flu shot and influenza vaccine; shares plunge

Novavax says FDA put hold on combination Covid-flu shot...

admin Oct 16, 2024  0  12

Frank Cappelleri on using charts to successfully navigate the markets

Frank Cappelleri on using charts to successfully naviga...

admin Jul 26, 2024  0  5